Does Antipsychotic Dose Reduction Lead To Better Functional Recovery In First Episode Psychosis: A Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,371,552.00
Summary
Can a person with a first episode of psychosis, once remitted, reduce their dosage of medication and still achieve better outcomes in functioning, physical health and brain volume, than if they had stayed on traditional maintenance doses of medication? This study will examine if using a dose reduction strategy in conjunction with an evidence based suite of psychosocial interventions leads to better social and vocational recovery and improved physical health and brain volume.
Rates Of Psychosis Onset In A High Risk Population
Funder
National Health and Medical Research Council
Funding Amount
$310,359.00
Summary
Older studies of people at risk of schizophrenia found that about 35% of them developed psychosis within 1 year. However the risk has decreased lately to as low as 10%. They may still become psychotic but take longer to do so, or they may not develop psychosis at all. We need to study this so that those not “at risk” are not needlessly treated. We will follow up “at risk” people and determine their 6 year outcome. We will do scans to see if there are any brain changes associated with psychosis.
Studies On The Expression Of Muscarinic Receptors: Implications For The Pathology Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$498,791.00
Summary
Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. This project will help define changes in the molecules in the brain of subjects with schizophrenia which are likely to be involved in two symptoms of the disorder, the psychoses and cognitive deficits. Understanding the cause of the cognitive deficits of schizophrenia is a high priority because they are the most disabilitating symptom of the disorder and do not respond to current drug treatments.
Antipsychotic Medication In First-episode Psychosis: An RCT To Assess The Risk-benefit Ratio
Funder
National Health and Medical Research Council
Funding Amount
$1,141,117.00
Summary
There has been an increasing emphasis on intervening early in psychotic disorders. A fundamental principle in early intervention is “to do no harm” and benefits must outweigh the risks of treatment. While antipsychotic medication is very effective and evidence-based form of treatment for positive symptoms in most first episode psychosis (FEP) patients it has risks. This study has the potential to determine whether antipsychotic medication should be the initial treatment option for FEP.
Predictors Of Outcome And Intervention In The ‘Ultra-High Risk’ For Psychosis Population
Funder
National Health and Medical Research Council
Funding Amount
$401,561.00
Summary
This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psychotic disorders and provide intervention to delay or prevent the onset of psychosis. A number of studies are planned, including researching disturbances in sense of self, neurocognitive factors, history of trauma and reaction to stress as predictive of future onset of psychosis, as well as a study of omega-3 fatty acids (fish oil) as an intervention for the ....This area of research is concerned with improving our ability to identify young help-seeking patients who are most at risk of developing psychotic disorders and provide intervention to delay or prevent the onset of psychosis. A number of studies are planned, including researching disturbances in sense of self, neurocognitive factors, history of trauma and reaction to stress as predictive of future onset of psychosis, as well as a study of omega-3 fatty acids (fish oil) as an intervention for these high risk young people.Read moreRead less
Early Detection Of Infants And Young Children With Autism
Funder
National Health and Medical Research Council
Funding Amount
$268,250.00
Summary
Autism is a severely handicapping condition adversely affecting social interaction, communication, behaviour, interests, and activities. Autism requires treatment at an early age (before 4 years). Despite finding that parents notice problems with their child's development within the first 2 years, on average diagnoses are made around 6 years of age. Treatment for autism should begin as early as possible to improve outcome. Diagnosis requires specialist assessment and these services are limited. ....Autism is a severely handicapping condition adversely affecting social interaction, communication, behaviour, interests, and activities. Autism requires treatment at an early age (before 4 years). Despite finding that parents notice problems with their child's development within the first 2 years, on average diagnoses are made around 6 years of age. Treatment for autism should begin as early as possible to improve outcome. Diagnosis requires specialist assessment and these services are limited. Therefore it is not possible to undertake such assessments with all children who have developmental problems. This project therefore proposes to evaluate a method for screening large populations of children for autism, thus enabling timely and more appropriate referral to assessment services. Previous work by the investigators has developed a potential screening tool (DBC Early Screen) for autism in young children under 4 years with developmental delay that has high levels of accuracy in identifying those infants and children who are at risk of autism and require specialist assessment. This project proposes to undertake a community field trial to assess the accuracy and reliability of this early screen and to establish its suitability for wide use as a population screening tool. The preliminary testing of DBC Early Screen demonstrated that a community field trial was feasible. The results of this study will facilitate the referral of infants and young children to specialist autism assessment services, thus enabling the commencement of appropriate early intervention for children and their families from an early age.Read moreRead less
Enabling Personalised Risk Assessment For Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$431,000.00
Summary
Bowel cancer screening will be most effective in disease prevention if it is applied proportionately to individual person's risk. Risk-based screening requires a risk calculator to assess personal risk. By utilising existing large, international datasets, I will identify the risk factors specific for different bowel cancer types and incorporate them to upgrade the prediction model that I have developed. This will achieve more accurate risk prediction to enable personalised risk-based screening.
The Efficacy Of N-acetyl Cysteine As An Adjunctive Treatment For First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$2,143,069.00
Summary
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.
Improving Physical Health Outcomes For Young People With Psychotic Disorders
Funder
National Health and Medical Research Council
Funding Amount
$189,384.00
Summary
Enduring psychotic disorders are associated with a reduced life expectancy by 25 years, which is mainly due to cardiovascular disease. This project will produce a training package that will improve clinician’s skills and knowledge of screening and treatment for physical health risk factors in young people with psychosis. This project will result in the development of an intervention for reducing the prevalence of these cardiovascular risk factors known to contribute to this early mortality.